Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 16/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911608 | 0.91 | PDE9A (0.42) | PDE9APDE5APDE1B | |
| SCHEMBL7905084 | 0.89 | PDE9A (0.41) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL7906942 | 0.87 | HHAT (0.42) | PDE9APDE5A | |
| SCHEMBL7912495 | 0.87 | PDE9A (0.39) | PDE9APDE5A | |
| SCHEMBL7907316 | 0.86 | MAPK1 (0.44) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL12045020 | 0.85 | LHCGR (0.43) | PDE9A | |
| SCHEMBL12045009 | 0.83 | PDE9A (0.43) | PDE9APDE5APDE1BPDE1A | |
| SCHEMBL1723634 | 0.82 | PDE9A (0.44) | PDE9APDE5APDE1B | |
| SCHEMBL7907352 | 0.81 | PDE9A (0.41) | PDE9APDE5APDE1BPDE1APDE1C | |
| SCHEMBL14827018 | 0.81 | PDE9A (0.46) | PDE9APDE5APDE1BPDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE5A 4/4885PDE1B 30/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | PDE9A 1/4885PDE5A 2/4885PDE1B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.